Vyome Holdings (HIND) EBITDA (2015 - 2026)
Vyome Holdings (HIND) posted EBITDA of -$862566.0 for Q2 2026, up 23.66% on a QoQ basis from -$1.1 million in Q1 2026, and down 166.07% year-over-year from $1.3 million in Q2 2025.
Powered by 
Analysis
Vyome Holdings (HIND) EBITDA (2015 - 2026) Analysis & Trends
Vyome Holdings has reported EBITDA for 12 years, with the latest figure at -$862566.0 in Q2 2026.
- On a quarterly basis, EBITDA fell 166.07% year-over-year to -$862566.0 in Q2 2026; TTM through Jun 2026 was -$11.9 million, a 1024.53% decrease from a year earlier, with the FY2025 full-year figure at -$10.5 million, down 938.67% from the prior year.
- EBITDA was -$862566.0 for Q2 2026 at Vyome Holdings, up from -$1.1 million in the prior quarter.
- The five-year high for EBITDA was -$198998.0 in Q1 2025, with the low at -$16.7 million in Q4 2022.
- Average EBITDA over 5 years is -$4.4 million, with a median of -$2.1 million recorded in 2024.
- The sharpest annual moves came in 2024 and 2025: EBITDA soared 92.76% in 2024, then sank 2951.59% in 2025.
- Over 5 years, EBITDA stood at -$16.7 million in 2022, then soared by 88.65% to -$1.9 million in 2023, then surged by 86.49% to -$256006.0 in 2024, then slumped by 429.31% to -$1.4 million in 2025, then soared by 36.35% to -$862566.0 in 2026.
- The last three EBITDA figures came in at -$862566.0 (Q2 2026), -$1.1 million (Q1 2026), and -$1.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | -862,566.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -862,566.00 |
| Mar 31, 2026 | -1.13 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Sep 30, 2025 | -8.57 Mn |
| Jun 30, 2025 | -324,189.00 |
| Mar 31, 2025 | -198,998.00 |
| Dec 31, 2024 | -256,006.00 |
| Sep 30, 2024 | -280,978.00 |
| Jun 30, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.21 Mn |
| Dec 31, 2023 | -1.90 Mn |
| Sep 30, 2023 | -3.88 Mn |
| Jun 30, 2023 | -3.98 Mn |
| Mar 31, 2023 | -5.63 Mn |
| Dec 31, 2022 | -16.69 Mn |
| Sep 30, 2022 | -12.30 Mn |
| Jun 30, 2022 | -9.24 Mn |
| Mar 31, 2022 | -8.11 Mn |
| Dec 31, 2021 | -37.52 Mn |
| Sep 30, 2021 | -14.42 Mn |